{"id":"rebif-clone-484-39","safety":{"commonSideEffects":[{"rate":"approximately 70%","effect":"Injection site reactions"},{"rate":"approximately 60%","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"approximately 30%","effect":"Headache"},{"rate":"approximately 25%","effect":"Fatigue"},{"rate":"approximately 10%","effect":"Depression"},{"rate":"approximately 5-10%","effect":"Elevated liver enzymes"},{"rate":"approximately 5%","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL5791251","moleculeType":null,"molecularWeight":"406.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon beta-1a binds to type I interferon receptors (IFNAR1/IFNAR2) on the surface of immune cells and oligodendrocytes, triggering intracellular signaling cascades that increase expression of anti-inflammatory genes and decrease pro-inflammatory cytokine production. This leads to reduced migration of immune cells across the blood-brain barrier and decreased demyelination in multiple sclerosis. The mechanism also includes upregulation of immunoregulatory factors and suppression of Th1 and Th17 cell differentiation.","oneSentence":"Rebif is an interferon beta-1a that activates interferon receptors on immune cells to modulate immune response and reduce inflammation in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:57.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (RRMS)"},{"name":"Clinically isolated syndrome (CIS) with high risk of developing MS"}]},"trialDetails":[{"nctId":"NCT00367484","phase":"PHASE4","title":"Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-05","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":460}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant-human interferon beta-1a","r-hIFN Beta-1a"],"phase":"marketed","status":"active","brandName":"Rebif® (clone 484-39)","genericName":"Rebif® (clone 484-39)","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Biologic","firstApprovalDate":"","aiSummary":"Rebif (clone 484-39) is a medication used to treat Relapsing Remitting Multiple Sclerosis. It is a recombinant human interferon beta-1a, administered subcutaneously.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}